Hong Kong Stocks Movement | ZYLOXTB (02190) Rises Over 3% as Intracranial Aneurysm Embolization Stent Gains Approval, Strengthening Neurointerventional Product Pipeline

Stock News11-27

ZYLOXTB (02190) surged more than 3%, reaching HK$25.52 by the time of writing, with a trading volume of HK$13.1441 million. The company announced via its official WeChat account that its "Tongqiao Feilong™ Intracranial Aneurysm Embolization Stent" has received approval from China's National Medical Products Administration (NMPA) for market launch.

The Tongqiao Feilong™ stent is designed for use alongside embolization coils, specifically targeting intracranial neurovascular diseases, and offers a new efficient solution for clinical treatment. Compared to similar products on the market, it provides superior wall apposition and imaging visibility, enhancing procedural safety and precision. Additionally, its comprehensive range of models caters to diverse clinical needs.

CITIC Securities noted that the stent employs DFT material weaving technology, ensuring clear imaging throughout the procedure, thereby improving visibility and safety. The approval of this stent is expected to bolster ZYLOXTB's neurointerventional product pipeline, enhance its integrated solutions, and support market share growth while sustaining rapid performance expansion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160234556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160234556","market":"sg","top_or_hot":-1,"title":"Hong Kong Stocks Movement | ZYLOXTB (02190) Rises Over 3% as Intracranial Aneurysm Embolization Stent Gains Approval, Strengthening Neurointerventional Product Pipeline","media":"Stock News","content":"<p>ZYLOXTB (02190) surged more than 3%, reaching HK$25.52 by the time of writing, with a trading volume of HK$13.1441 million. The company announced via its official WeChat account that its \"Tongqiao Feilong™ Intracranial Aneurysm Embolization Stent\" has received approval from China's National Medical Products Administration (NMPA) for market launch.</p>\n<p>The Tongqiao Feilong™ stent is designed for use alongside embolization coils, specifically targeting intracranial neurovascular diseases, and offers a new efficient solution for clinical treatment. Compared to similar products on the market, it provides superior wall apposition and imaging visibility, enhancing procedural safety and precision. Additionally, its comprehensive range of models caters to diverse clinical needs.</p>\n<p>CITIC Securities noted that the stent employs DFT material weaving technology, ensuring clear imaging throughout the procedure, thereby improving visibility and safety. The approval of this stent is expected to bolster ZYLOXTB's neurointerventional product pipeline, enhance its integrated solutions, and support market share growth while sustaining rapid performance expansion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Movement | ZYLOXTB (02190) Rises Over 3% as Intracranial Aneurysm Embolization Stent Gains Approval, Strengthening Neurointerventional Product Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Movement | ZYLOXTB (02190) Rises Over 3% as Intracranial Aneurysm Embolization Stent Gains Approval, Strengthening Neurointerventional Product Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZYLOXTB (02190) surged more than 3%, reaching HK$25.52 by the time of writing, with a trading volume of HK$13.1441 million. The company announced via its official WeChat account that its \"Tongqiao Feilong™ Intracranial Aneurysm Embolization Stent\" has received approval from China's National Medical Products Administration (NMPA) for market launch.</p>\n<p>The Tongqiao Feilong™ stent is designed for use alongside embolization coils, specifically targeting intracranial neurovascular diseases, and offers a new efficient solution for clinical treatment. Compared to similar products on the market, it provides superior wall apposition and imaging visibility, enhancing procedural safety and precision. Additionally, its comprehensive range of models caters to diverse clinical needs.</p>\n<p>CITIC Securities noted that the stent employs DFT material weaving technology, ensuring clear imaging throughout the procedure, thereby improving visibility and safety. The approval of this stent is expected to bolster ZYLOXTB's neurointerventional product pipeline, enhance its integrated solutions, and support market share growth while sustaining rapid performance expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1160234556","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160234556","pubTimestamp":1764228987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZYLOXTB (02190) surged more than 3%, reaching HK$25.52 by the time of writing, with a trading volume of HK$13.1441 million. The company announced via its official WeChat account that its \"Tongqiao...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1100":"医疗保健设备","02190":"归创通桥","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"港股动向|ZYLOXTB(02190)涨超3%颅内动脉瘤栓塞支架获批强化神经介入产品管线","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"ZYLOXTB (02190) surged more than 3%, reaching HK$25.52 by the time of writing, with a trading volume of HK$13.1441 million. The company announced via its official WeChat account that its \"Tongqiao Feilong™ Intracranial Aneurysm Embolization Stent\" has received approval from China's National Medical Products Administration (NMPA) for market launch.\nThe Tongqiao Feilong™ stent is designed for use alongside embolization coils, specifically targeting intracranial neurovascular diseases, and offers a new efficient solution for clinical treatment. Compared to similar products on the market, it provides superior wall apposition and imaging visibility, enhancing procedural safety and precision. Additionally, its comprehensive range of models caters to diverse clinical needs.\nCITIC Securities noted that the stent employs DFT material weaving technology, ensuring clear imaging throughout the procedure, thereby improving visibility and safety. The approval of this stent is expected to bolster ZYLOXTB's neurointerventional product pipeline, enhance its integrated solutions, and support market share growth while sustaining rapid performance expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160234556","isCrawlerRequest":true}